Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia

Abstract The aim of the study is to determine the effects of monocular 0.125% atropine daily treatment on the longer axial length (AL) eyes in children with pediatric anisometropia. This was a retrospective cohort study. The charts of children with anisometropia (aged 6–15 years) who had a > 0.2-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Po-Hsiang Kao, Lan-Hsin Chuang, Chi-Chun Lai, Shin-Yi Chen, Ken-Kuo Lin, Jiahn-Shing Lee, Chiun-Ho Hou, Chueh-Tan Chen, Yu-Kai Kuo, Chi-Chin Sun, Chun-Fu Liu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/011dab51d8e94e77b39de3144c371846
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:011dab51d8e94e77b39de3144c371846
record_format	dspace
spelling	oai:doaj.org-article:011dab51d8e94e77b39de3144c3718462021-11-08T10:51:51ZEvaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia10.1038/s41598-021-96414-42045-2322https://doaj.org/article/011dab51d8e94e77b39de3144c3718462021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96414-4https://doaj.org/toc/2045-2322Abstract The aim of the study is to determine the effects of monocular 0.125% atropine daily treatment on the longer axial length (AL) eyes in children with pediatric anisometropia. This was a retrospective cohort study. The charts of children with anisometropia (aged 6–15 years) who had a > 0.2-mm difference in AL between the two eyes were reviewed. Children who received monocular treatment of 0.125% atropine in the eye with longer AL were included for final analysis. The main outcome measure was the difference in AL between the two eyes after treatment. Regression analysis was used to model the changes in AL according to the time of treatment in both eyes. Finally, forty eyes in 20 patients (mean age 10.2 years) were included in the analyses. During the treatment period, AL was controlled in the treated eyes (p = 0.389) but elongated significantly in the untreated eyes (p < 0.001). The difference in AL between the treated and untreated eyes decreased from 0.57 to 0.22 mm (p < 0.001) after the 1-year treatment period. In the regression model, the best fit for the relationship between changes in AL and time during the treatment period in the treated eyes was the quadratic regression model with a concave function. In conclusion, these data suggest that 0.125% atropine daily is an effective treatment to reduce the interocular difference of AL in eyes with axial anisometropia. This pilot study provides useful information for future prospective and larger studies of atropine for the treatment of pediatric axial anisometropia.Po-Hsiang KaoLan-Hsin ChuangChi-Chun LaiShin-Yi ChenKen-Kuo LinJiahn-Shing LeeChiun-Ho HouChueh-Tan ChenYu-Kai KuoChi-Chin SunChun-Fu LiuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Po-Hsiang Kao Lan-Hsin Chuang Chi-Chun Lai Shin-Yi Chen Ken-Kuo Lin Jiahn-Shing Lee Chiun-Ho Hou Chueh-Tan Chen Yu-Kai Kuo Chi-Chin Sun Chun-Fu Liu Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia
description	Abstract The aim of the study is to determine the effects of monocular 0.125% atropine daily treatment on the longer axial length (AL) eyes in children with pediatric anisometropia. This was a retrospective cohort study. The charts of children with anisometropia (aged 6–15 years) who had a > 0.2-mm difference in AL between the two eyes were reviewed. Children who received monocular treatment of 0.125% atropine in the eye with longer AL were included for final analysis. The main outcome measure was the difference in AL between the two eyes after treatment. Regression analysis was used to model the changes in AL according to the time of treatment in both eyes. Finally, forty eyes in 20 patients (mean age 10.2 years) were included in the analyses. During the treatment period, AL was controlled in the treated eyes (p = 0.389) but elongated significantly in the untreated eyes (p < 0.001). The difference in AL between the treated and untreated eyes decreased from 0.57 to 0.22 mm (p < 0.001) after the 1-year treatment period. In the regression model, the best fit for the relationship between changes in AL and time during the treatment period in the treated eyes was the quadratic regression model with a concave function. In conclusion, these data suggest that 0.125% atropine daily is an effective treatment to reduce the interocular difference of AL in eyes with axial anisometropia. This pilot study provides useful information for future prospective and larger studies of atropine for the treatment of pediatric axial anisometropia.
format	article
author	Po-Hsiang Kao Lan-Hsin Chuang Chi-Chun Lai Shin-Yi Chen Ken-Kuo Lin Jiahn-Shing Lee Chiun-Ho Hou Chueh-Tan Chen Yu-Kai Kuo Chi-Chin Sun Chun-Fu Liu
author_facet	Po-Hsiang Kao Lan-Hsin Chuang Chi-Chun Lai Shin-Yi Chen Ken-Kuo Lin Jiahn-Shing Lee Chiun-Ho Hou Chueh-Tan Chen Yu-Kai Kuo Chi-Chin Sun Chun-Fu Liu
author_sort	Po-Hsiang Kao
title	Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia
title_short	Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia
title_full	Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia
title_fullStr	Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia
title_full_unstemmed	Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia
title_sort	evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/011dab51d8e94e77b39de3144c371846
work_keys_str_mv	AT pohsiangkao evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT lanhsinchuang evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT chichunlai evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT shinyichen evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT kenkuolin evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT jiahnshinglee evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT chiunhohou evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT chuehtanchen evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT yukaikuo evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT chichinsun evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia AT chunfuliu evaluationofaxiallengthtoidentifytheeffectsofmonocular0125atropinetreatmentforpediatricanisometropia
_version_	1718442489826770944

Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia

Ejemplares similares